Strategic expansion Endpoint Clinical recently expanded through the acquisition of Bluefin Clinical, signaling a broader scope in clinical supply forecasting and planning technology. This creates cross-sell opportunities into the combined customer base and potential upsell of Elosity R3 and AI-driven trial insights to new and existing clients.

R3 platform growth The launch of Elosity R3 and the associated enhancements to RTSM, clinical supply, and AI-driven insights indicate a strong focus on next-generation technology. This presents a sales window for upselling advanced RTSM capabilities, data analytics services, and integration with current customer ecosystems.

Global reach With headquarters in Raleigh and offices across the US, EU, and Asia, Endpoint Clinical has a geographically diversified footprint. This supports targeting multinational sponsors needing global RTSM support and region-specific regulatory compliance, as well as cross-border supply planning.

Industry leadership Recognition as a Leader in the Everest Group RTSM PEAK Matrix and ongoing product releases position Endpoint as a credible partner for sponsors seeking proven, scalable solutions. Emphasize differentiators such as proactive issue resolution and seamless trial integration in outreach.

Talent and leadership changes Recent CHRO transition may influence decision-makers and organizational priorities. Leverage this period to present stable, scalable partnerships and highlight capabilities in talent augmentation, program governance, and customer success to reassure prospective clients.